Pyxis Oncology PYXS 深 沪
等待开盘 10-21 09:30:00 美东时间
1.84
+0.080
+4.55%
华盛通- 最 高1.90
- 今 开1.76
- 成交量 52.27万股
- 最 低 1.73
- 昨 收 1.76
- 总市值 15.35万
- 52周最高 5.55
- 市盈率 静 --
- 换手率 0.63%
- 52周最低 1.03
- 委 比 17.85%
- 总股本 8.34万
- 历史最高 19.00
- 量 比 0.81
- 振 幅 9.66%
- 历史最低 0.8332
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pyxis Oncology收跌6.67%，成交额153.07万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:44
Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement
PYXIS ONCOLOGY, INC. Common Stock This Supplement No. 1 to Prospectus Supplement (this "Supplement") supplements and amends the Prospectus Supplement dated November 26, 2025 (the "Prospectus Supplement"). This Supplement should be read in conjunction with the Prospectus Supplement and the Prospectus...
09-30 04:24
Pyxis Oncology Announces Proposed Public Offering
Pyxis Oncology has launched a public offering of its common stock and warrants, with proceeds to fund its lead clinical program, MICVO, targeting recurrent/metastatic head and neck squamous cell carcinoma. The offering includes common stock, pre-funded warrants, and accompanying common warrants exercisable upon shareholder approval of a charter amendment. The warrants' exercise is contingent on the amendment's effectiveness and the release of ove...
09-29 20:24
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology Inc. (NASDAQ:PYXS) on Wednesday shared updated data from its Phase 1 trial evaluating micvotabart pelidotin (MICVO). The ongoing global study tested the drug as a monotherapy for patients facing second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma. Prom...
09-10 01:42
Pyxis Oncology Reports Promising MICVO Phase 1 Results
The latest announcement is out from Pyxis Oncology ( ($PYXS) ). On September 9,...
09-09 19:58
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology Inc (NASDAQ:PYXS) shares gained 5.91% to $4.12 in overnight trading Tuesday, following the company’s leadership announcement and an upcoming clinical data webcast. New CEO Brings Track Record Of Major Deals The Boston-based clinical-stage biopharmaceutical company appointed Thomas Civ...
09-09 16:01
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology will host a live webcast on September 9, 2026, at 7:30 a.m. ET to present updated clinical data on micvotabart pelidotin (MICVO) for treating recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The event will feature scientific insights, treatment landscape implications, efficacy and safety results, and future clinical plans. MICVO, an antibody-drug conjugate targeting EDB+FN in the tumor microenvironment, is be...
09-08 20:01
Pyxis Oncology Appoint Thomas Civik Chairman, CEO, Effective Sept. 4
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026. Mr. Ci...
09-08 19:32
